Mast cell tryptase: a new biomarker in patients with stable coronary artery disease

Deliargyris, Efthymios N.; Upadhya, Bharathi; Sane, David C.; Dehmer, Gregory J.; Pye, Joseph; Smith, Sidney C.; Boucher, William; Theoharides, Theoharis C.

doi:10.1016/j.atherosclerosis.2004.09.008

Cited by 61 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Furthermore, levels of serum tryptase, a major product of mast cells, appear to be increased in persons with the metabolic syndrome 31 and have even been proposed as a new biomarker of coronary artery disease. 32 The precise immunologic mechanisms by which SCIT influences the allergen-specific immune response and the immune system in general are not completely understood.…”

Section: Discussionmentioning

confidence: 99%

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality

Linneberg

Jacobsen

Jespersen

et al. 2012

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality

Linneberg

Jacobsen

Jespersen

et al. 2012

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Raised tryptase levels were observed in non allergic patients with significant chronic coronary artery disease as a result of chronic lowgrade inflammatory activity present in the atherosclerotic plaques [82]. Tryptase levels were found fivefold increased after 5 min, tenfold increased after 15 and 60 min and twice as low in the free-symptom period in patients with unstable angina immediately after the onset of chest pain with electrocardiographic signs of ischemia [83].…”

Section: Innate Release Of Pro-inflammatory Molecules: Common Pathwaymentioning

confidence: 99%

Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management

Kounis¹

2016

Clinical Chemistry and Laboratory Medicine (CCLM)

312

421

View full text Add to dashboard Cite

Kounis syndrome has been established as a hypersensitivity coronary disorder induced by various conditions, drugs, environmental exposures, foods and coronary stents. Allergic, hypersensitivity, anaphylactic and anaphylactoid reactions are associated with this syndrome. Vasospastic allergic angina, allergic myocardial infarction and stent thrombosis with occluding thrombus infiltrated by eosinophils and/or mast cells constitute are the three reported, so far, variants of this syndrome. Apart from coronary arteries, it affects the cerebral and mesenteric arteries. Its manifestations are broadening and its etiology is continuously increasing. Kounis syndrome is a ubiquitous disease which represents a magnificent natural paradigm and nature's own experiment in a final trigger pathway implicated in cases of coronary artery spasm and plaque rupture. Kounis syndrome seems to be not a rare disease but an infrequently diagnosed clinical entity which has revealed that the same mediators released from the same inflammatory cells are also present and in acute coronary events of non allergic etiology. These cells are not only present in the culprit region before plaque erosion or rupture but they release their contents just before an actual coronary event. Therefore, awareness of etiology, epidemiology, pathogenesis and clinical manifestations seems to be important for its prognosis, diagnosis, treatment, prevention.

show abstract

“…In a recent study [65], tryptase levels were elevated in patients with non-allergic acute coronary syndromes with higher concentration in the ST segment depression group of patients and it was postulated that tryptase may be a potential new marker characterizing the unstable plaque. Tryptase levels were found also elevated in non-allergic patients with significant coronary artery disease as a result of chronic low-grade inflammatory activity present in the atherosclerotic plaques [66]. It is proposed that tryptase measurements may emerge as a novel way of identifying asymptomatic patients with coronary artery disease and represent a new biomarker of therapeutic efficacy in these patients [66].…”

Section: Common Pathway Between Allergic and Non-allergic Coronary Symentioning

confidence: 99%

“…Tryptase levels were found also elevated in non-allergic patients with significant coronary artery disease as a result of chronic low-grade inflammatory activity present in the atherosclerotic plaques [66]. It is proposed that tryptase measurements may emerge as a novel way of identifying asymptomatic patients with coronary artery disease and represent a new biomarker of therapeutic efficacy in these patients [66]. Therefore, the same substances from the same cells are present in both acute allergic episodes and acute coronary syndromes.…”

Section: Common Pathway Between Allergic and Non-allergic Coronary Symentioning

confidence: 99%

Kounis syndrome (allergic angina and allergic myocardial infarction): A natural paradigm?

Kounis¹

2006

International Journal of Cardiology

472

436

View full text Add to dashboard Cite

Mast cell tryptase: a new biomarker in patients with stable coronary artery disease

Cited by 61 publications

References 24 publications

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality

Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management

Kounis syndrome (allergic angina and allergic myocardial infarction): A natural paradigm?

Contact Info

Product

Resources

About